- Home
- CATX vs LYEL Comparison
CATX vs LYEL Comparison
Compare CATX & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- LYEL
- Stock Information
- Founded
- CATX 1983
- LYEL 2018
- Country
- CATX United States
- LYEL United States
- Employees
- CATX N/A
- LYEL N/A
- Industry
- CATX Medical/Dental Instruments
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- CATX Health Care
- LYEL Health Care
- Exchange
- CATX Nasdaq
- LYEL Nasdaq
- Market Cap
- CATX 239.0M
- LYEL 207.7M
- IPO Year
- CATX N/A
- LYEL 2021
- Fundamental
- Price
- CATX $3.97
- LYEL $9.84
- Analyst Decision
- CATX Strong Buy
- LYEL Sell
- Analyst Count
- CATX 11
- LYEL 2
- Target Price
- CATX $12.90
- LYEL $15.00
- AVG Volume (30 Days)
- CATX 1.3M
- LYEL 148.8K
- Earning Date
- CATX 08-11-2025
- LYEL 08-06-2025
- Dividend Yield
- CATX N/A
- LYEL N/A
- EPS Growth
- CATX N/A
- LYEL N/A
- EPS
- CATX N/A
- LYEL N/A
- Revenue
- CATX $1,471,000.00
- LYEL $65,000.00
- Revenue This Year
- CATX N/A
- LYEL N/A
- Revenue Next Year
- CATX N/A
- LYEL N/A
- P/E Ratio
- CATX N/A
- LYEL N/A
- Revenue Growth
- CATX N/A
- LYEL N/A
- 52 Week Low
- CATX $1.60
- LYEL $7.65
- 52 Week High
- CATX $16.55
- LYEL $38.40
- Technical
- Relative Strength Index (RSI)
- CATX 61.19
- LYEL 52.64
- Support Level
- CATX $3.33
- LYEL $9.11
- Resistance Level
- CATX $3.69
- LYEL $10.41
- Average True Range (ATR)
- CATX 0.38
- LYEL 0.61
- MACD
- CATX 0.01
- LYEL 0.04
- Stochastic Oscillator
- CATX 64.23
- LYEL 70.77
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.